Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

BACKGROUND: Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD). It is thought to act via postsynaptic receptors in the prefrontal cortex, modulating executive functions including the regulation of attention. Attention is affected ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Karen, Watt, Hilary, Golemme, Mara, Perry, Richard J., Ritchie, Craig, Wilson, Danielle, Pickett, James, Fox, Chris, Howard, Robert, Malhotra, Paresh A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340683/
https://www.ncbi.nlm.nih.gov/pubmed/35915506
http://dx.doi.org/10.1186/s13063-022-06190-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340683/
https://www.ncbi.nlm.nih.gov/pubmed/35915506
http://dx.doi.org/10.1186/s13063-022-06190-3

Ejemplares similares